148 related articles for article (PubMed ID: 30509751)
1. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients.
Rodríguez-Sánchez E; Navarro-García JA; Aceves-Ripoll J; Álvarez-Llamas G; Segura J; Barderas MG; Ruilope LM; Ruiz-Hurtado G
Nefrologia (Engl Ed); 2019; 39(2):184-191. PubMed ID: 30509751
[TBL] [Abstract][Full Text] [Related]
2. The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients.
Xu TY; Zhang Y; Li Y; Zhu DL; Gao PJ
Ren Fail; 2014 Jun; 36(5):666-72. PubMed ID: 24575880
[TBL] [Abstract][Full Text] [Related]
3. Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis.
Kobusiak-Prokopowicz M; Kaaz K; Marciniak D; Karolko B; Mysiak A
Kidney Blood Press Res; 2021; 46(6):749-757. PubMed ID: 34801997
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment.
Musiał K; Zwolińska D
Cell Stress Chaperones; 2011 Jan; 16(1):97-103. PubMed ID: 20821177
[TBL] [Abstract][Full Text] [Related]
5. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.
Pulido-Olmo H; García-Prieto CF; Álvarez-Llamas G; Barderas MG; Vivanco F; Aranguez I; Somoza B; Segura J; Kreutz R; Fernández-Alfonso MS; Ruilope LM; Ruiz-Hurtado G
Clin Sci (Lond); 2016 Apr; 130(7):525-38. PubMed ID: 26733721
[TBL] [Abstract][Full Text] [Related]
6. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
[TBL] [Abstract][Full Text] [Related]
8. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
10. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.
Rysz J; Banach M; Stolarek RA; Mikhailidis DP; Cialkowska-Rysz A; Pokoca L; Piechota M; Baj Z
Int Urol Nephrol; 2011 Jun; 43(2):491-8. PubMed ID: 19953348
[TBL] [Abstract][Full Text] [Related]
11. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.
Gluba-Brzózka A; Michalska-Kasiczak M; Franczyk B; Nocuń M; Toth P; Banach M; Rysz J
Lipids Health Dis; 2016 Feb; 15():22. PubMed ID: 26843213
[TBL] [Abstract][Full Text] [Related]
12. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis.
Söder PO; Meurman JH; Jogestrand T; Nowak J; Söder B
J Periodontal Res; 2009 Aug; 44(4):452-8. PubMed ID: 18973519
[TBL] [Abstract][Full Text] [Related]
17. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
18. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of systemic levels of neutrophilic enzymes in patients with hypertension and chronic periodontitis.
Türkoğlu O; Barış N; Tervahartiala T; Şenarslan Ö; Sorsa T; Atilla G
J Periodontol; 2014 Jul; 85(7):908-16. PubMed ID: 24224962
[TBL] [Abstract][Full Text] [Related]
20. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
